MedTrace Logo

A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers

NCT02225912 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-01-16

No results posted yet for this study

Summary

The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.

Conditions

  • Upper Respiratory Infections

Interventions

OTHER

PrevinC

DRUG

placebo

Sponsors & Collaborators

  • BioHealth Technologies Inc.

    lead INDUSTRY

Study Design

Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02225912 on ClinicalTrials.gov